The Long Run with Luke Timmerman: Recent Episodes
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton, if he were alive, would appreciate biotech. Today’s scientific entrepreneurs must be ready for the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina, and resilience, to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.
Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.
Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.
Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.
Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients.
Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.
Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.
Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.
Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.
Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.
John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.
Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.
Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.
David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.
Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.
Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.
Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.
Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale.
Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.
Jonathan Bricker, professor in the cancer prevention program at Fred Hutchinson Cancer Center, on how to quit smoking with help from tech and biotech tools.
Leslie Williams, CEO of Boston-based hC Bioscience, on developing transfer RNA therapies.
Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.
Ted Love, chairman of BIO, and Dr. Alan Anderson, executive director of Sickle Forward, on how to improve quality of life for sickle cell disease patients around the world.
Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.
Jeff Stein, CEO of San Diego-based Cidara Therapeutics, on a long-lasting drug against flu.
Abe Ceesay, CEO of Boston-based Rapport Therapeutics, on a precision medicine approach to neuroscience drug discovery.
Jimi Olaghere is one of the first patients to have been functionally cured of sickle cell disease with a CRISPR gene-edited cell therapy.
David Younger and Randolph Lopez, co-founders of A-Alpha Bio, on using synthetic biology and AI to discover new biologic drugs.
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.
Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.
Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.
Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.
Jeff Jonker, CEO of San Diego-based Belharra Therapeutics, on the renaissance in small molecule drug discovery.
Nancy Stagliano, CEO of South San Francisco-based Neuron23, on bringing precision medicine to neuroscience drug discovery.
Jeff Huber, co-founder and general partner at Triatomic Capital, on his career path in tech, and then biotech.
Lori Lyons-Williams, CEO of Abdera Therapeutics, on developing targeted radiopharmaceuticals for cancer.
Fred Appelbaum, a physician, scientist and leader at the Fred Hutchinson Cancer Center, on 'Living Medicine,' his new book about the development of bone marrow transplantation and the rise of cell therapy.
Colin Hill, co-founder and CEO of Aitia, on digging deep into biological datasets and finding new drug targets.
Yung Lie, president and CEO of Damon Runyon Cancer Research Foundation, on advancing cancer research by supporting young scientists with bold and brave ideas.
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
John Maraganore, former founding CEO of Alnylam Pharmaceuticals, on his life in biotech and developing RNA interference as a new class of medicine.
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.
DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.
Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.
Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.
Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.
Samantha Truex, CEO of Upstream Bio, on a new approach to treating severe asthma and other inflammatory diseases.
Jo Viney, CEO of Seismic Therapeutic, on discovering new treatments for autoimmune disease.
Ivan Liachko, CEO of Seattle-based Phase Genomics, on assembling accurate genomes and interactomes. He also discusses immigrating from Ukraine as a child, and what brought him and his family to the US.
Dr. Sanduk Ruit of the Tilganga Institute in Kathmandu on restoring eyesight with affordable cataract surgery for the developing world.
Ivana Magovcevic-Liebisch, CEO of Vigil Neuroscience, on precision neuroscience drug development.
Rahul Singhvi, CEO of Resilience, on rethinking the model for manufacturing of advanced biologics, gene and cell therapies.
Chris Gibson, co-founder and CEO of Recursion, on using new tools to industrialize drug discovery.
Lewis Cantley and Siddhartha Mukherjee, co-founders of Faeth Therapeutics, on fighting cancer with food and drug combinations.
Michele Andrasik, a clinical health psychologist at the Fred Hutchinson Cancer Research Center, on improving community outreach and diversity in clinical trials.
Derrell Porter, CEO of CellEvolve, on a new approach to commercializing cell therapies.
Praveen Tipirneni, CEO of Morphic Therapeutic, on targeting integrins with small molecules.
Vineeta Agarwala, general partner with Andreesen Horowitz's bio fund, on investing in therapeutics, diagnostics and digital health.
Nello Mainolfi, CEO of Kymera Therapeutics, on targeted protein degrading small molecule drugs.
Jeff Bluestone, CEO of Sonoma Biotherapeutics, on engineered T-reg cell therapies for autoimmunity.
Keolu Fox, assistant professor at UC San Diego, on genome sequencing of indigenous populations.
James Sabry, global head of pharma partnering for Roche, on partnering in a time of scientific abundance.
Sekar Kathiresan, co-founder and CEO of Verve Therapeutics, on a gene edited single shot for cardiovascular disease.
Peter Kolchinsky of RA Capital on making drugs affordable, and keeping incentives for drug discovery.
Joel Marcus, chairman of Alexandria Real Estate Equities, on building in biotech clusters.
Janelle Anderson on venture capital and off-the-shelf cell therapy at Century Therapeutics
Jay Bradner, president of Novartis Institutes for Biomedical Research, on his journey from open biology advocate to pharma leadership.
Abbie Celniker of Third Rock Ventures on her career, and chipping away at gender inequities in biotech.
Elias Zerhouni, president of R&D at Sanofi, on immigration in science and the importance of government science funding.
Ep. 2 of The Long Run With Luke Timmerman. Interview with Katrine Bosley, CEO of Editas Medicine.
Ep. 1 of The Long Run, a biotech podcast with Luke Timmerman. Conversation with Alnylam Pharmaceuticals CEO John Maraganore.